MUNICH—More than four years median overall survival was reported in patients treated with an inhibitor of anaplastic lymphoma kinase (ALK) for their ALK gene rearranged non-small cell lung cancer (NSC
MUNICH—More than four years median overall survival was reported in patients treated with an inhibitor of anaplastic lymphoma kinase (ALK) for their ALK gene rearranged non-small cell lung cancer (NSCLC) in a single-arm phase two study reported at the 2018 annual congress of the European Society for Medical Oncology, ESMO.
http://212.114.167.162/slidecenter/esmo2018/attendee/confcal/session/calendar?q=felip
“The information presented here showed that for patients included in the ASCEND 3 trial—ALK positive patients previously treated with chemotherapy—who received ceritinib as their first ALK inhibitor there [was] an overall survival of 51 months. This is really encouraging,” said lead author Enriqueta Felip MD PhD, medical oncologist and Chair of the Thoracic Malignancies Group at Vall d’Hebron University Hospital in Barcelona, Spain, talking to the Audio Journal of Oncology.
Tags
Related Episodes
Jonathan W. Goldman MD and David R Spigel MD; ASCO 2026: Patients with RET Fusion Positive Early Stage Non-Small Cell Lung Cancer Benefit from Selpercatinib: LIBRETTO-432 Early Results
Patients with RET Fusion Positive Early Stage Non-Small Cell Lung Cancer Benefit from Selpercatinib: LIBRETTO-432 Early Results An interview with: Jonathan W. Goldman MD, Director of Clinical Trials i
Rukhmini Bandyopadhyay MD, AACR 2026: AI “Pathomics Platform” Selects Immunotherapy, Predicts Outcome for Patients with Metastatic Non-Small Cell Lung Cancer
AI “Pathomics Platform” Selects Immunotherapy, Predicts Outcome for Patients with Metastatic Non-Small Cell Lung Cancer An interview with: Rukhmini Bandyopadhyay MD, Postdoctoral Fellow, The Universi
Jonathan Wesley Riess MD; 2026 AACR: Investigational KRAS(ON) Inhibitor Zoldonrasib Showed Effective and Durable Responses in Patients With Advanced G12D-mutated Lung Cancer
Investigational KRAS(ON) Inhibitor Zoldonrasib Showed Effective and Durable Responses in Patients With Advanced G12D-mutated Lung Cancer An interview with: Jonathan Wesley Riess MD, Professor of Medic